account_id none on file
legal_name Edgewise Therapeutics, Inc.
ticker EWTX
cik 1710072
domain edgewisetx.com
linkedin_company_url https://www.linkedin.com/company/edgewisetx/
entry_point_account_id none on file
name Edgewise Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 25 executives 1 family 0
why_nownone on file
callsnone on file
filings
If any prolonged government shutdown or disruption occurs, including due to any public health emergencies, travel restrictions, or staffing shortages, it could significantly impact the ability of the FDA and other regulatory authorities to timely review and process our regulatory submissions and provide feedback on our clinical development plans, which could have a material adverse effect on our business and our anti
filing / Aug 6, 2026 / receipt
In February 2023, the lease was modified to occupy an additional 9,624 square feet of office space, with aggregate payments of approximately $1.5 million over the initial 7.3 year term, plus our share of operating expenses.
filing / Aug 6, 2026 / receipt
government appropriations, changes in agency personnel, public health emergencies, travel restrictions, staffing shortages, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.
filing / Aug 6, 2026 / receipt
The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.
filing / Aug 6, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.
filing / Aug 6, 2026 / receipt
If any prolonged government shutdown or disruption occurs, including due to any public health emergencies, travel restrictions, or staffing shortages, it could significantly impact the ability of the FDA and other regulatory authorities to timely review and process our regulatory submissions and provide feedback on our clinical development plans, which could have a material adverse effect on our business and our anti
filing / May 7, 2026 / receipt
In February 2023, the lease was modified to occupy an additional 9,624 square feet of office space, with aggregate payments of approximately $1.5 million over the initial 7.3 year term, plus our share of operating expenses.
filing / May 7, 2026 / receipt
government appropriations, changes in agency personnel, public health emergencies, travel restrictions, staffing shortages, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.
filing / May 7, 2026 / receipt
The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.
filing / May 7, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.
filing / May 7, 2026 / receipt
Further, under the new leadership at the HHS under the current administration, agency reorganization, mass layoffs due to the reduction in force initiative and other measures implemented by the Department of Government Efficiency may impact the normal operations of the FDA as well as other federal agencies.
filing / May 7, 2026 / receipt
Associate Scientist/Scientist Pharmacology | {"ats": "greenhouse", "city": "Boulder", "state": "CO", "job_id": "4399681009", "remote": false, "category": "other", "function": "retail", "location": "Bo
company_statement / Sep 9, 2026 / receipt
executives
| Arlene Morris | Director | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2024-05-07 | Chief Executive Officer, appointed | sec_8k |
mcp_package_hint
slug edgewise-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$